STOCK TITAN
  1. Home
  2. Sec-filings
  3. NERV
  4. [Form 4] Minerva Neurosciences, Inc. Insider Trading Activity

Minerva Neurosciences (NERV) CFO awarded 680,000 stock options at $4.6800

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Minerva Neurosciences, Inc. reported that SVP, CFO and Secretary Frederick W. Ahlholm received a grant of stock options covering 680,000 shares of Common Stock. The options have an exercise price of $4.6800 per share and expire on June 2, 2036.

According to the footnote, the option vests 25% on June 3, 2027 and then in equal quarterly installments over three years. Following this grant, Ahlholm holds 680,000 stock options directly, and the filing does not show any related share sales or purchases.

Positive

  • None.

Negative

  • None.
Insider Ahlholm Frederick W
Role SVP, CFO and Secretary
Type Security Shares Price Value
Grant/Award Employee Stock Option (right to buy) 680,000 $0.00 --
Holdings After Transaction: Employee Stock Option (right to buy) — 680,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 680,000 options Employee Stock Option grant to CFO on June 3, 2026
Exercise price $4.6800 per share Strike price for employee stock options
Underlying shares 680,000 shares Common Stock underlying the options
Options after transaction 680,000 options Total options held directly following grant
Initial vesting date June 3, 2027 25% of options vest on this date
Expiration date June 2, 2036 Options expire if not exercised by this date
Employee Stock Option (right to buy) financial
"security_title: Employee Stock Option (right to buy)"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
underlying security title financial
"underlying_security_title: Common Stock"
vests 25% financial
"The option vests 25% on June 3, 2027"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ahlholm Frederick W
(Last)(First)(Middle)
C/O MINERVA NEUROSCIENCES, INC.
1500 DISTRICT AVENUE
(Street)
BURLINGTON MASSACHUSETTS 01803
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Minerva Neurosciences, Inc. [ NERV ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
SVP, CFO and Secretary
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)$4.6806/03/2026A680,000 (1)06/02/2036Common Stock680,000$0680,000D
Explanation of Responses:
1. The option vests 25% on June 3, 2027 and then in equal quarterly installments over 3 years thereafter.
/s/ Frederick Ahlholm06/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Minerva Neurosciences (NERV) report for Frederick W. Ahlholm?

Minerva Neurosciences (NERV) reported that SVP and CFO Frederick W. Ahlholm received a grant of employee stock options for 680,000 shares. These options are compensation-related awards, not open-market purchases or sales, and give him the right to buy Common Stock at a fixed price.

What is the exercise price of the new stock options granted at Minerva Neurosciences (NERV)?

The newly granted employee stock options at Minerva Neurosciences (NERV) have an exercise price of $4.6800 per share. This price is the cost Ahlholm must pay per share to convert the options into Common Stock if he chooses to exercise them in the future.

How many Minerva Neurosciences (NERV) shares are covered by the CFO’s new option grant?

The CFO’s new employee stock option grant at Minerva Neurosciences (NERV) covers 680,000 underlying shares of Common Stock. This entire amount is shown as owned following the transaction, reflecting his direct option position after the compensation award was recorded.

What is the vesting schedule of the new NERV stock options granted to the CFO?

The new NERV stock options vest 25% on June 3, 2027, with the remaining 75% vesting in equal quarterly installments over three years. Vesting means the options become exercisable over time rather than all at once on the grant date.

When do the newly granted Minerva Neurosciences (NERV) options expire?

The newly granted Minerva Neurosciences (NERV) employee stock options expire on June 2, 2036. After this expiration date, Ahlholm can no longer exercise them, so any decision to turn options into shares must occur before that deadline.

Did the Minerva Neurosciences (NERV) Form 4 show any share sales or purchases by the CFO?

The Minerva Neurosciences (NERV) Form 4 shows a compensation-related acquisition of employee stock options by the CFO, not open-market share purchases or sales. The transaction is coded as a grant or award, with no reported disposals or cash market trades in this filing.